Alexza shares plunge on FDA extension; Verastem readies unusual biotech IPO;

@FierceBiotech: What's making Big pay for mobile tech? Drives to streamline trials ops and, of course, sell more drugs. Story | Follow @FierceBiotech

@JohnCFierce: Scientists strip the brake off of T cells in mouse study, amp up immune response. Article | Follow @JohnCFierce

@RyanMFierce: Educators jumping aboard the Big Data bandwagon with industry clamoring for help #bioinformatics--. Article | Follow @RyanMFierce

@MarkHFierce: B.U. has found some genetic triggers behind the onset of menopause. Info could help treat age-related diseases. Release | Follow @MarkHFierce

@FierceMedDev: An interesting read: Med tech consolidation brings a need for focus. Here are 2 ways to get it. Article | Follow @FierceMedDev

> Shares of Alexza Pharmaceuticals ($ALXA) slid 19% this morning after the biotech reported that the FDA had extended its review of the anti-psychotic Adasuve by three months. Report

> Spectrum Pharmaceuticals ($SPPI) reported some positive new data for its lymphoma drug Zevalin. Patients taking a Zevalin combo had a distinctly higher two-year survival rate compared to patients receiving chemo alone. Story

> The preclinical stage biotech Verastem plans to roll out an unusual $45 million IPO this week. In its SEC filings the biotech, which was founded by Christoph Westphal, has noted that the company's financial backers have committed to buying about a third of the offering. Story

> Exelixis ($EXEL) is claiming positive preliminary data from a Phase II study of cabozantinib in hepatocellular carcinoma. Release

Pharma News

@FiercePharma: Patent cliff + R&D disappointments + regulatory issues + economic woes = a tough 2012 for pharma, Fitch says. More | Follow @FiercePharma

> Tysabri label change could add $1B to sales. News

> Gov't probes laundry list of drugmakers. Story

> Roche workers protest contract hiring in Poland. News

> GSK chief wants Olympics lab to outlast games. Article

> Why drugmakers are so enamored of rare-disease meds. Item

Medical Devices News

> Stent advances expected to prop up European market. Story

> Covidien's Almeida to add title of chairman. Piece

> EU breast implant scandal may affect FDA's view on faster device approvals. Article

IT News

> Big Pharma testing waters with mobile tech. More

> Oracle injects genomics capability into analytics platform. News

> Medidata chief calls company 'the cloud' for clinical data. Story

> Consumers to pharma: Let's be Facebook friends (or not). Item

> Oracle, Parexel among leaders in CTMS market poised to hit $1.3B. More

> FDA brings new work flow software into its labs. Article

And Finally... Chinese officials have approved the world's first vaccine for hepatitis E. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.